Debrosse Maxime, Shergill Sukhman, Shah Achal, Patel Kaiwal, Gulati Amitabh, Rajput Kanishka
Yale University School of Medicine, Department of Anesthesiology, United States.
Weill Cornell Medicine, Department of Anesthesiology, United States.
Interv Pain Med. 2022 Mar 2;1(3):100076. doi: 10.1016/j.inpm.2022.100076. eCollection 2022 Sep.
To assess the comparative effectiveness and harms of trigger point injections (TPI) for myofascial neck and back pain.
Electronic literature databases were searched to identify articles pertaining to TPI for chronic myofascial neck and back pain. Searches were done from database start dates up to April 2020. Inclusion criteria were randomized controlled trials, cohorts, and case control studies. Pain, functional outcomes, and harms were extracted. Outcome time points were divided into short term (7 days to <6 weeks), intermediate term (6 weeks to < 3 months), long term (3 months to < 6 months), and longest term (>6 months). Quality assessment was done using the Cochrane Back Review Group (CBRG) checklist for RCTs, and the Newcastle-Ottawa Quality Assessment Scale for cohort and case control studies.
14 studies met inclusion criteria. Six studies compared TPI of Botulinum toxin A (five with Onabutulinum toxin A, and one with Abobotulinum toxin A) with normal saline (NS). Two of the Onabotulinum toxin A studies showed greater pain improvement in the Onabotulinum toxin A group at short, intermediate, compared with NS. The Abobotulinum study showed pain improvement at short, intermediate, and long terms. Of note Onabotulinum toxin A was associated with improved anxiety and depression in two studies. Two studies compared Onabotulinum toxin A to local anesthetic, one to methylprednisolone, and one to dry needling (DN), all of which showed no difference. One study compared Ozone to Lidocaine and DN, and it showed no difference. Two studies compared sterile water to NS; they both found no difference in pain outcomes at the short term time point. However one of these two studies showed improved pain at intermediate, long, and longest terms in the sterile water group. Tropisetron showed no difference vs. NS. Adverse effects were mostly reported for Onabotulinum toxin A and Abobotulinum toxin A.
Given the mixed results, we are unable to conclude whether an injectate composition is superior to another, or make recommendations in that regard. Further studies will help elucidate the ideal injectate composition and parameters.
评估触发点注射(TPI)治疗颈部和背部肌筋膜疼痛的相对有效性和危害。
检索电子文献数据库,以识别与TPI治疗慢性颈部和背部肌筋膜疼痛相关的文章。检索时间从数据库起始日期至2020年4月。纳入标准为随机对照试验、队列研究和病例对照研究。提取疼痛、功能结局和危害等数据。结局时间点分为短期(7天至<6周)、中期(6周至<3个月)、长期(3个月至<6个月)和最长期(>6个月)。使用Cochrane背部综述小组(CBRG)的随机对照试验清单以及队列研究和病例对照研究的纽卡斯尔-渥太华质量评估量表进行质量评估。
14项研究符合纳入标准。6项研究将A型肉毒杆菌毒素的TPI(5项使用昂博肉毒毒素A,1项使用阿泊肉毒毒素A)与生理盐水(NS)进行比较。两项使用昂博肉毒毒素A的研究表明,与NS相比,昂博肉毒毒素A组在短期和中期疼痛改善更明显。阿泊肉毒毒素的研究表明在短期、中期和长期均有疼痛改善。值得注意的是,两项研究中昂博肉毒毒素A与焦虑和抑郁的改善有关。两项研究将昂博肉毒毒素A与局部麻醉剂进行比较,一项与甲基强的松龙比较,一项与干针疗法(DN)比较,所有这些比较均未显示出差异。一项研究将臭氧与利多卡因和DN进行比较,未显示出差异。两项研究将无菌水与NS进行比较;它们在短期时间点均未发现疼痛结局有差异。然而,这两项研究中的一项表明,无菌水组在中期、长期和最长期疼痛有所改善。托烷司琼与NS相比未显示出差异。不良反应大多报告于昂博肉毒毒素A和阿泊肉毒毒素A。
鉴于结果不一,我们无法得出一种注射剂成分是否优于另一种的结论,也无法在这方面提出建议。进一步的研究将有助于阐明理想的注射剂成分和参数。